What Is the False Claims Act and How Does It Protect Corporations?

Liability arises when a person or entity presents, causes to be presented, or uses a false record or statement to obtain payment or approval from the government, or when the person knowingly retains overpayments without prompt repayment. The statute covers not only outright fabrications but also material omissions, certifications of compliance with regulations that are not met, and submission of claims despite knowing the underlying work was defective or not performed as promised. Corporations often encounter exposure through government contract performance, healthcare billing (particularly Medicare and Medicaid claims), defense contracting, and grant administration. The breadth of the statute means that even indirect or derivative false statements can create liability if they were submitted with the requisite knowledge.

Knowledge under the statute includes actual knowledge, deliberate ignorance, and reckless disregard for the truth. A corporation cannot shield itself from liability by claiming it did not know a false claim was submitted if the company maintained a practice or policy that fostered such ignorance, or if senior management ignored red flags about compliance. This standard is notably broader than common-law fraud, which typically requires proof of intent to deceive. Courts have found liability even when the company did not benefit financially, provided the false claim was presented with the requisite mental state. For corporations, this means that negligence or poor internal controls are not a defense; the focus is on whether the company or its agents acted with knowledge, deliberate ignorance, or reckless disregard.

Treble damages mean the court multiplies the actual damages by three. If a corporation submitted false claims totaling $100,000 and was found liable, the treble damages award would be $300,000, plus per-claim civil penalties. This punitive structure reflects Congress's intent to deter fraud and incentivize relators to bring qui tam actions. Actual damages are typically calculated as the amount the government overpaid or the value the government lost by not receiving what it was promised. In contract disputes, courts may consider the difference between what was promised and what was actually delivered, or the cost of remediation. Corporations cannot escape treble damages by arguing good faith or partial performance; liability triggers the full statutory remedy once the false claim element is established.

A qui tam action allows a private relator to file suit on behalf of the United States, with the relator entitled to between 15 and 30 percent of any recovery (or judgment), plus reasonable attorney fees and costs. The government retains the right to intervene and take over the litigation. When the government declines to intervene, the relator proceeds as the real party in interest, and the relator's incentive to pursue the claim aggressively is substantial. Corporations often discover False Claims Act exposure only after a qui tam complaint is filed under seal and later unsealed. The qui tam mechanism creates a powerful private enforcement tool that supplements government resources and has resulted in billions of dollars in recoveries over the statute's history.

After a qui tam complaint is filed, it is placed under seal (typically for 60 days, renewable) while the government investigates and decides whether to intervene. During the seal period, the defendant is not notified of the lawsuit, which can complicate early preparation. Once the seal is lifted or the government makes its intervention decision, the case proceeds to answer, motion practice, and discovery. Many False Claims Act cases involve voluminous document production, including contracts, invoices, performance records, compliance certifications, and communications regarding the challenged claims. Defendants often move to dismiss on grounds that the complaint fails to plead falsity with sufficient particularity, or that the relator lacks standing. In New York federal courts, practitioners have observed that delays in unsealing or incomplete notice to corporate defendants can create procedural complications, particularly if the company's response deadlines are triggered without full awareness of the claims. Early engagement with experienced counsel is critical to protect document preservation, manage discovery scope, and evaluate settlement posture.

Corporations may argue that the underlying claim was not false, that the government had actual knowledge of the alleged falsity and did not object, or that the relator lacks standing or failed to plead falsity with particularity. The government-knowledge defense is narrow; it requires showing that the specific government official with authority over the claim had actual knowledge, not merely that some government employee was aware of facts that might have prompted investigation. Materiality is also a defense: if the false statement or omission was not material to the government's decision to pay, liability may not attach. Corporations may also challenge whether the defendant acted with the requisite knowledge or whether the claim was truly false under the contract terms and applicable regulations. These defenses require careful factual development and often depend on contract interpretation, regulatory compliance analysis, and testimony regarding what the government knew and when.

Corporations should establish clear policies requiring accurate submission of all claims and certifications to the government, with documented procedures for verifying compliance before submission. Training programs for employees involved in billing, contract performance, and regulatory certification help ensure awareness of False Claims Act obligations. Internal audit functions should periodically review claims, invoices, and performance records against contract terms and regulatory requirements. Documentation of compliance efforts, remediation of identified deficiencies, and prompt repayment of any overpayments discovered are essential. Many corporations also implement compliance hotlines and investigation procedures to address employee concerns about potential false claims. These measures do not eliminate liability but can mitigate damages, support settlement negotiations, and demonstrate corporate commitment to legal compliance if a qui tam action is filed.

Healthcare providers and medical device manufacturers may face False Claims Act exposure in connection with bodily injury claims if they submit false information about patient injuries, treatment necessity, or device safety to Medicare, Medicaid, or other federal programs. For example, a provider might submit claims for procedures based on false diagnoses or misrepresentations about patient condition, or a manufacturer might certify that a device is safe when known defects existed. The intersection creates compounded liability: the underlying bodily injury claim and the false submission to the government. Corporations should ensure that medical records, billing documentation, and regulatory submissions are consistent and accurate, particularly when federal program funding is involved.